Blood online
Home About Blood Authors Subscriptions Permission Advertising Public Access contact us
 

 
Advanced
Current Issue
First Edition
Future Articles
Archives
Submit to Blood
Search
American Society of Hematology
Meeting Abstracts
Email Alerts
Prepublished online as a Blood First Edition Paper on July 5, 2002; DOI 10.1182/blood-2001-12-0293.

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
2001-12-0293v1
100/10/3633    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Right arrow Rights and Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Cooper, M. A.
Right arrow Articles by Caligiuri, M. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Cooper, M. A.
Right arrow Articles by Caligiuri, M. A.
Related Collections
Right arrow Immunobiology
Right arrow Apoptosis
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

arrow to previous article Previous Article  |  Table of Contents  |  Next Article next article arrow

Blood, 15 November 2002, Vol. 100, No. 10, pp. 3633-3638

IMMUNOBIOLOGY

In vivo evidence for a dependence on interleukin 15 for survival of natural killer cells

Megan A. Cooper, Jennifer E. Bush, Todd A. Fehniger, Jeffrey B. VanDeusen, Ross E. Waite, Yang Liu, Hector L. Aguila, and Michael A. Caligiuri

From the Departments of Internal Medicine, Division of Hematology/Oncology; Veterinary Biosciences; Molecular Virology, Immunology and Medical Genetics; and Pathology; The James Cancer Hospital and Comprehensive Cancer Center, The Ohio State University, Columbus; and the Center for Immunotherapy, University of Connecticut Health Center, Farmington.


    Abstract
Top
Abstract
Introduction
Materials and methods
Results
Discussion
References

Cellular homeostasis requires a balance between cell production, cell survival, and cell death. Production of natural killer (NK) cells from bone marrow precursor cells requires interleukin 15 (IL-15); however, very little is known about the factors controlling survival of mature NK cells in vivo. Because mice deficient in IL-15 (IL-15-/- mice) fail to develop NK cells, it is not known whether mature NK cells can survive in an environment lacking IL-15. We hypothesized that IL-15 might indeed be required for survival of mature NK cells in vivo. Freshly isolated NK cells labeled with 5-(and-6)-carboxyfluorescein diacetate, succinimidyl ester (CFSE) were adoptively transferred into IL-15-/- mice and littermate control (IL-15+/-) mice. Within 36 hours after transfer, NK cells were detected in both IL-15-/- and IL-15+/- mice; however, significantly more (P < .003) CFSE-positive (CFSE+) NK cells were found in control mice than in IL-15-/- mice. By 5 days, similar numbers of CFSE+ NK cells were still easily detected in IL-15+/- mice, whereas no CFSE+ NK cells survived in IL-15-/- mice. Furthermore, mice with severe combined immunodeficiency treated with the Fab fragment of a blocking antibody recognizing a signaling subunit of the IL-15 receptor, IL-2/15Rbeta , had a significant (~90%) loss of NK cells compared with control mice. Finally, NK cells from Bcl-2 transgenic mice that were adoptively transferred into IL-15-/- mice did survive. These results show conclusively that IL-15 is required for mature NK cell survival in vivo and suggest that IL-15 mediates its effect on NK cell survival by means of Bcl-2. (Blood. 2002;100:3633-3638)

© 2002 by The American Society of Hematology.

    Introduction
Top
Abstract
Introduction
Materials and methods
Results
Discussion
References

Natural killer (NK) cells are innate immune lymphocytes that provide at least 2 critical functions during early host defense: cytolysis of infected or transformed cells regulated by a unique repertoire of newly defined receptors, and early provision of cytokines and chemokines for activation of innate and adaptive immune responses.1-5 NK cells develop in the bone marrow microenvironment, where their differentiation requires the actions of the stromal cell-derived cytokine interleukin 15 (IL-15).6,7 Very little is known about the factors controlling survival and homeostasis of mature NK cells in vivo after their release from the bone marrow.

IL-15 is a widely expressed, pleiotropic cytokine first described in 1994 on the basis of its ability to stimulate proliferation of an IL-2-dependent cell line.8,9 It was subsequently found to share 2 receptor subunits with IL-2. Both cytokines signal through the shared IL-2/15Rbeta and common gamma  chain ([gamma c] also shared by IL-4, IL-7, IL-9, and IL-21).10,11 IL-15 also uses its own unique receptor, IL-15Ralpha , which confers high-affinity binding of this cytokine and may, in certain cases, also transduce an intracellular signal.12-14 Studies in murine models have shown that NK cell differentiation is dependent on IL-15 signaling. Because of defects in production, NK cells are deficient or absent in mice with targeted disruptions of IL-15 (IL-15-/-),15 IL-15 receptor subunits (IL-15Ralpha -/-, IL-2/15Rbeta -/-, and gamma c-/-),16-18 or IL-15 signaling components (Jak3-/- and STAT5a/b-/-).19,20 Likewise, mice generated to overexpress IL-15 have large expansions of NK cells.21,22 The discovery that a patient with an NK-deficient form of severe combined immunodeficiency (SCID) lacked expression of the IL-2/15Rbeta chain23 further highlights the importance of IL-15 signaling for NK cell production in vivo. In contrast, mice lacking IL-2, which shares signaling components with IL-15 and also can induce NK cell differentiation in vitro, were shown to have normal NK cell function,24 a finding that distinguishes IL-15 as the critical in vivo signaling molecule necessary for NK cell development.

Although it is known that IL-15 is required for NK cell development, the factors necessary for maintaining NK cell homeostasis in the periphery are unknown. Because cellular homeostasis requires a balance between cell production, cell survival, and cell death, it is reasonable to assume that a common factor might control more than one of these processes. We hypothesized that, given the wide expression of IL-15 and the absolute requirement of this cytokine for the production of NK cells, IL-15 might also regulate NK cell survival. We previously reported that IL-15 can sustain human NK cell survival in vitro.25 In this study, we investigated the survival of NK cells labeled with 5-(and-6)-carboxyfluorescein diacetate, succinimidyl ester (CFSE) that were adoptively transferred into mice lacking IL-15 (IL-15-/-) or littermate control mice (IL-15+/-). Our results show for the first time that IL-15 is absolutely required for maintenance of mature NK cell survival in vivo.


    Materials and methods
Top
Abstract
Introduction
Materials and methods
Results
Discussion
References

Mice and reagents

IL-15-/- mice (C57BL/6 background) were provided by Immunex (Seattle, WA)15 and bred at Ohio State University. Wild-type (wt), Ly5.1-positive (Ly5.1+), and SCID mice (all on C57BL/6 background) were purchased from Jackson Laboratories (Bar Harbor, ME). These mice were maintained in specific pathogen-free conditions at Ohio State University, and all experiments were carried out with approval from the Institutional Animal Care and Use Committee. Bcl-2 transgenic (Bcl-2tg) mice (C57BL/6 background), described previously,26 were provided by Dr H. L. Aguila (University of Connecticut). Bcl-2tg mice were maintained at the University of Connecticut Health Sciences Animal Facility, and all experiments with them were conducted in accordance with the university's institutional guidelines. Phycoerythrin (PE)-conjugated or fluorescein isothiocyanate (FITC)-conjugated monoclonal antibodies (mAbs) recognizing the following antigens were purchased from Pharmingen (San Diego, CA): DX5 (PE), CD45.1 (Ly5.1, PE), NK1.1 (PE, FITC, and allophycocyanin [APC]), murine Bcl-2 (PE), and isotype-control antibodies (Abs). The CFSE was purchased from Molecular Probes (Eugene, OR). Recombinant murine IL-15 (muIL-15) was a gift from Immunex. Antimouse IL-2/15Rbeta (TM-beta 1, rat IgG2b) was isolated from hybridoma supernatants27 (a gift from T. Tanaka), and control Ab (rat IgG) was purchased from Sigma (St Louis, MO).

Isolation of murine NK cells

NK cells were isolated from the spleens of wt, Ly5.1+, SCID, or Bcl-2tg mice. Single-cell suspensions of splenocytes were made, red blood cells lysed, and viable lymphocytes isolated by density-gradient centrifugation using Lympholyte-M (Cedarlane Laboratories, Hornby, ON, Canada). Cells from wt, Ly5.1+, and SCID mice were resuspended in phosphate-buffered saline (PBS) plus 2% fetal-calf serum (FCS), and NK cells were negatively selected by using a labeling kit from StemCell Technologies (Vancouver, BC, Canada) that included biotinylated Abs recognizing CD3, CD5, CD22, T-cell receptor (TCR)alpha beta , GR-1, TER119, and F4/80. This was followed by secondary labeling of Ab-coated cells with magnetic beads in accordance with the manufacturer's recommendations (StemCell Technologies). For enrichment of Bcl-2tg NK cells, lymphocytes were labeled with biotinylated Abs recognizing CD22 (Pharmingen), F480 (Caltag, Burlingame, CA), CD19, CD3, TCR, CD5, Ter119, and 8C5 (Biosource, Camarillo, CA), and this was followed by secondary labeling with anti-biotin magnetic beads (Miltenyi Biotec, Germany). All cells were then passed through magnetically activated cell-sorter LS columns (Miltenyi Biotec), and NK cells were obtained by negative selection. The eluted cells were stained with DX5 or NK1.1 and isotype-control mAbs and analyzed for NK cell purity by flow cytometry. Purity ranged from 50% to 80% for wt, Ly5.1+, and SCID NK cells and was about 20% for Bcl-2tg NK cells.

Adoptive transfer of wt and Bcl-2tg NK cells into IL-15-/- mice

NK cells were purified from wt or Ly5.1 mice (6-10 weeks old) as described above. NK cells were labeled for 15 minutes at room temperature with CFSE (1 µM) in PBS, washed twice with 10% FCS, once with PBS, and resuspended in sterile PBS for injection. For experiments with wt NK cells, equal numbers of NK cells (7 × 105 to 2.5 × 106 cells/mouse) were injected into the tail veins of IL-15-/- and littermate control IL-15+/- mice (7-18-weeks old; mean age, 13.2 weeks). For experiments with Bcl-2tg cells, 1 to 1.5 × 106 NK cells were injected into the orbital vein of IL-15-/- and littermate control mice (8-10 weeks old). Mice were killed 36 hours, 5 days, or 7 days after transfer, and lymphocytes from the blood, liver, or spleen were isolated. Liver cells were first digested with collagenase IV (0.02%) and DNase I (10 U/mL) at 37°C for 40 minutes. Then, both digested liver cells and splenocytes were processed into single-cell suspensions. This was followed by density centrifugation with Lympholyte-M and collection of viable cells. Samples were stained with DX5-PE, CD45.1 (Ly5.1)-PE, and/or NK1.1-PE or NK1.1-APC and the appropriate isotype-control mAb. Flow cytometry was then used to analyze CFSE-positive (CFSE+) transferred NK cells. At least 100 000 events were collected for each organ, with as many as 1 000 000 events analyzed, depending on the number of cells available. For all experiments, similar numbers of events were analyzed for tissues from IL-15-/- and control mice.

Calculation of NK cell recovery

NK cell recovery is expressed as the percentage of NK cells originally transferred. To determine this value, total cell counts from the spleen, liver, and blood were multiplied by the percentage of CFSE+ NK cells found in each tissue and then divided by the original number of NK cells transferred (equal to the total number of cells transferred times the percentage of NK cells). This value represents the NK cell recovery from an individual tissue. To determine differences in total NK cell recovery, the numbers of NK cells recovered from all 3 tissues were added and then divided by the original number of NK cells transferred.

Administration of an Ab to the muIL-2/15Rbeta chain

SCID mice (3 per group) were injected intraperitoneally twice daily with 500 µg Fab fragments of TM-beta 1 (anti-IL-2/15Rbeta ) or control Ab (rat IgG) for 7 days. To obtain Fab fragments, whole Ab was digested at a concentration of 10 mg/mL for 4 hours at 37°C in a buffer containing 20 mM sodium phosphate (pH 7.0), 2 mM EDTA (ethylenediaminetetraacetic acid), 10 mM cysteine, and 2% wt/vol mercuripapain (Sigma). Cleavage was arrested by the addition of iodoacetamide to a final concentration of 20 mM for 30 minutes at room temperature. Iodoacetamide was removed by overnight dialysis in PBS. The resultant Fab fragments were analyzed for purity by sodium dodecyl sulfate-polyacrylamide gel electrophoresis, quantitated, and sterile filtered for injection.

Measurement of Bcl-2 expression in NK cells

To determine initial Bcl-2 levels, enriched NK cells were stained immediately for intracellular Bcl-2. The remaining NK cells were plated in 96-well, U-bottomed plates in RPMI 1640 plus 10% FCS at a density of 2.3 to 3.0 × 105 cells/well and cultured with muIL-15 (10 ng/mL) or medium alone. Cells were harvested after 12 and 24 hours of culture and stained for intracellular Bcl-2. Briefly, for experiments in which NK cells were less than 80% pure, cells were first stained with NK1.1-FITC or isotype-control mAb. For higher-purity NK cell preparations or after staining with NK1.1, cells were permeabilized by washing with 0.03% saponin (Sigma) and incubated for 20 minutes at 4°C with a PE-conjugated Ab recognizing murine Bcl-2. Bcl-2 protein levels were then measured by flow cytometry.

Assessment of nuclear degradation of NK cells by propidium iodide (PI) staining

Enriched NK cells were plated in 96-well, U-bottomed plates at a density of 2.3 to 3.0 × 105 cells/well in medium (RPMI 1640 plus 10% FCS). Cells were cultured with muIL-15 or medium alone. After 24 hours, cell membranes were permeabilized with 0.25% saponin (Sigma), and this was followed by addition of 100 µg/mL RNase A (10 mg/mL stock) and 50 µg/mL PI solution (1 mg/mL stock). PI incorporation was measured by flow cytometry.

Statistical and flow cytometric analyses

The Student t test was used for statistical analysis, with a P value of .05 or less considered to represent significance. All flow cytometric analyses except those in the Bcl-2tg experiments were done with an XL flow cytometer (Beckman Coulter, Fullerton, CA), and data were analyzed with WinMDI software (Joseph Trotter, Scripps Research Institute, La Jolla, CA). For the Bcl-2tg experiments, an FACSCalibur flow cytometer (BD Biosciences, San Jose, CA) was used and data were analyzed with CellQuest (BD Biosciences) and WinMDI software.


    Results
Top
Abstract
Introduction
Materials and methods
Results
Discussion
References

Adoptive transfer of NK cells Into IL-15-/- and control mice

Freshly isolated murine NK cells were enriched from wt or Ly5.1+ mice and labeled with CFSE. Equal numbers of cells were then adoptively transferred into IL-15-/- mice (Ly5.2+), which lack NK cells, and littermate control IL-15+/- mice (Ly5.2+), which have functional NK cells.15 The DX5 antigen was used to track transferred NK cells because of the bright staining obtained with this Ab; however, more than 98% of the enriched NK cells were consistently positive for both DX5 (DX5+) and NK1.1 (NK1.1+) before the adoptive transfer (data not shown). At 1.5 days, transferred CFSE+DX5+ NK cells were detected in the spleen, blood, and liver of both IL-15-/- and IL-15+/- mice (Figure 1A). However, assessment of total recovery of NK cells from all 3 tissues revealed that greater than 7-fold more transferred NK cells were recovered from control mice than from mice lacking IL-15 (P < .003; Figure 1A and Table 1). Therefore, NK cells could successfully be transferred into IL-15-/- mice but did not appear to survive. By 5 days, transferred NK cells had disappeared completely from IL-15-/- mice, whereas a substantial population of CFSE+DX5+ NK cells was still present in littermate control (IL-15+/-) mice (Figure 1A and Table 1). In adoptive transfer experiments in which NK cells were isolated from Ly5.1+ mice, transferred cells could be further distinguished as CFSE+Ly5.1+ and were identified in the spleens of both IL-15-/- and control mice 1.5 days after the transfer but were undetectable in IL-15-/- mice by 5 days (Figure 1B).


View larger version (61K):
[in this window]
[in a new window]
 
Figure 1. Detection of transferred NK cells in IL-15-/- and control mice. CFSE+ NK cells were assessed by flow cytometry 1.5 and 5 days after transfer into IL-15-/- and control (IL-15+/-) mice. (A) The spleen (SP), blood (BL), and liver (LV) were analyzed for the presence of CFSE+DX5+ NK cells. Cells were gated on viable lymphocytes. Transferred cells are highlighted in boxes, and the percentages for each organ are shown. At day 1.5, transferred cells were detectable in both IL-15-/- and control mice, with significantly higher numbers of NK cells recovered from the controls (7.4 ± 0.7 fold; P < .003; total NK cells). At day 5, transferred NK cells were undetectable in IL-15-/- mice but still present in control mice. Results are representative of 4 independent experiments at 1.5 days and 4 independent experiments at 5 days. (B) For 3 of the 1.5-day and 5-day adoptive transfer experiments, NK cells were isolated from Ly5.1+ mice, labeled with CFSE, and transferred into IL-15-/- and control mice (both of which are Ly5.2+). Consistent with the results shown in panel A, transferred cells could be detected as CFSE+Ly5.1-PE+ in the spleens of IL-15-/- and control mice killed at day 1.5 but were undetectable in IL-15-/- mice at day 5.


                              
View this table:
[in this window]
[in a new window]
 
Table 1. Recovery of transferred NK cells from IL-15-/- and control (IL-15+/-) mice at days 1.5 and 5. 

In all the tissues assessed (spleen, blood, and liver), significantly more adoptively transferred NK cells were recovered from control mice than from IL-15-/- mice (Table 1). Similar to the distribution of NK cells in wt mice, most transferred NK cells were found in the spleen, with lower numbers recovered from the blood and liver (Table 1). Interestingly, there was no significant difference in the percentages of CFSE+ NK cells recovered in tissues from control mice at 1.5 and at 5 days, suggesting that transferred NK cells were maintained in vivo at constant levels during the time points examined. CFSE labeling can also detect proliferation, since the fluorescence of this dye is halved with each cellular division. At the time points examined in the current study, the transferred NK cells appeared uniform in their CFSE intensity and thus did not appear to have cycled in vivo. This result suggests that the observed differences in NK cell recovery were not due to NK cell proliferation in control (IL-15+/-) mice. Furthermore, transferred cells were still detectable in control mice for at least 10 days after adoptive transfer (data not shown), indicating that the lack of IL-15, rather than technical difficulties in detecting cells, accounted for the inability to detect cells in IL-15-/- mice after 5 days.

In vivo blockade of the IL-2/15Rbeta chain results in a significant loss of NK cells

The role of IL-15 in NK cell survival was again examined in vivo, this time by using mice with an intact NK cell compartment. SCID mice, which lack T and B cells but have normal NK cell function, were treated for one week with the Fab fragment of a blocking Ab that recognizes the muIL-2/15Rbeta chain (TM-beta 1) or with control Fab. IL-15 and IL-2 both can signal through the shared IL-2/15Rbeta chain, but because of their absence of T cells, SCID mice lack expression of IL-2, thus allowing exclusive examination of IL-15 signaling with the anti-IL-2/15Rbeta Ab. After 7 days of Ab treatment, there was a significant difference in the number of NK cells recovered from mice treated with anti-IL-2/15Rbeta and controls, with about 90% fewer splenic NK cells recovered from mice given anti-IL-2/15Rbeta (P < .0004; Figure 2). This disappearance of NK cells was not due to Fc, immune-mediated clearance of cells, since a single injection of whole TM-beta 1 Ab completely cleared NK cells within 24 hours, whereas one injection of the Fab fragment used in these experiments had no effect on NK cell numbers at this early time point (data not shown). Thus, the failure of NK cells to survive in mice given anti-IL-2/15Rbeta , similar to the disappearance of NK cells in IL-15-/- mice, can be attributed solely to the inhibition of IL-15 signaling.


View larger version (17K):
[in this window]
[in a new window]
 
Figure 2. NK cells recovered from SCID mice treated with an Ab against the IL-2/15Rbeta chain or control Ab. SCID mice (3 per group) were treated twice daily (500 µg/dose) with the Fab fragment of a blocking Ab against the IL-2/15Rbeta chain (TM-beta 1) or control Fab (rat IgG). Shown is a flow histogram gated on splenic lymphocytes and stained for DX5-PE after 7 days of treatment with control Fab (A) or anti-IL-2/15Rbeta Fab (B). Results from 2 representative animals are shown. (C) Significantly fewer splenic NK cells were recovered from mice treated with anti-IL-2/15Rbeta than from controls (38.2 ± 3.8 × 103 versus 372.1 ± 28.2 × 103 NK cells/spleen). The asterisk indicates P less than .0004. Error bars indicate SEM.

IL-15 maintains murine NK cell Bcl-2 expression

We reported previously that IL-15 activation of human NK cells induces up-regulation of the lymphocyte antiapoptotic factor Bcl-2 in vitro, resulting in a survival benefit.25 In the current study, we found that murine NK cells cultured in medium alone were not able to maintain Bcl-2 expression, whereas cells cultured with IL-15 did (Figure 3A). Likewise, consistent with results of previous studies in humans25 and mice,28 PI nuclear staining showed that murine NK cells cultured in medium underwent apoptosis more quickly than cells cultured with IL-15 (Figure 3B). This suggests one possible mechanism by which IL-15 may prevent apoptosis and maintain survival of mature NK cells in vivo.


View larger version (12K):
[in this window]
[in a new window]
 
Figure 3. Maintenance of Bcl-2 protein and survival of NK cells cultured with IL-15. (A) Freshly isolated murine NK cells were stained for baseline (0 hour) expression of Bcl-2 protein by using intracellular flow cytometry and again after culture for 12 and 24 hours with 10 ng/mL IL-15 (shaded area) or medium alone (dark line). NK cells cultured in IL-15 maintained significantly higher mean fluorescence intensity (MFI) of Bcl-2 staining than those cultured in medium alone (158.9 ± 80.4 versus 58.1 ± 17.6; P = .05; n = 4 at 12 hours and 152.4 ± 58.3 versus 28.9 ± 21.0; P = .03; n = 3 at 24 hours). Results are representative of four 12-hour and three 24-hour experiments. (B) Viability of enriched NK cells cultured in the presence of IL-15 (10 ng/mL) for 24 hours was assessed with PI staining. NK cells cultured with IL-15 had 50% less cell death than cells cultured in medium alone (n = 3). Results from one representative experiment are shown.

NK cells from Bcl-2tg mice survive in IL-15-/- mice

To assess the importance in vivo of our finding that IL-15 can maintain Bcl-2 levels in murine NK cells in vitro, NK cells from mice overexpressing Bcl-2 (Bcl-2tg mice) were adoptively transferred into IL-15-/- mice and littermate controls. The Bcl-2tg donor mice used in these experiments globally overexpress human Bcl-2 in all hematopoietic cells, and NK cells from these mice have prolonged survival in vitro.26 Enriched Bcl-2tg NK cells were first labeled with CFSE and then transferred into IL-15-/- and control mice (2 pairs). At 1.5 days, spleen, liver, and blood samples from these mice were examined for the presence of CFSE+ NK cells. In contrast to the results of the adoptive transfer experiments with wt NK cells, similar numbers of Bcl-2tg NK cells were detected in IL-15-/- and control mice (Figure 4). One week after transfer, Bcl-2tg splenic NK cells could still be detected in equal numbers in both IL-15-/- and control mice (average, 0.025% and 0.03% CFSE+NK1.1+ cells, respectively; data not shown; n = 2). These findings further support the idea that Bcl-2 is a key survival factor for NK cells and, together with our in vitro data, suggest that IL-15 mediates its effect on NK cell survival by means of Bcl-2.


View larger version (55K):
[in this window]
[in a new window]
 
Figure 4. Bcl-2tg NK cells are maintained in IL-15-/- mice. CFSE-labeled, enriched NK cells from Bcl-2tg mice (purity about 20%) were adoptively transferred into IL-15-/- and control mice (n = 2 pairs). At 1.5 days after transfer, the spleen (SP; upper panels) and blood (BL; lower panels) were analyzed for the presence of NK1.1+CFSE+ NK cells. Cells were gated on viable lymphocytes, and transferred NK cells are highlighted. Similar numbers of Bcl-2tg NK cells were detected in both IL-15-/- (left) and IL-15+/- (right) mice. Data from one experiment are shown. Transferred Bcl-2tg NK cells were also detected in similar numbers in IL-15-/- and control mice 7 days after transfer (data not shown).


    Discussion
Top
Abstract
Introduction
Materials and methods
Results
Discussion
References

In this study, we used 2 separate models to demonstrate conclusively that IL-15 is necessary for the survival of NK cells in vivo. Furthermore, we showed that IL-15 can maintain Bcl-2 expression in vitro and that NK cells overexpressing Bcl-2 survive longer than wt NK cells when transferred into IL-15-/- mice. Thus, these results suggest a possible mechanism by which IL-15 can sustain murine NK cell survival in vivo.

It is conceivable that the observed in vivo effects of IL-15 on NK cell survival were indirect; however, the data presented here and our previous in vitro studies with human NK cells25 suggest strongly that IL-15 can directly promote NK cell survival. IL-15 protein is expressed by a variety of immune and nonimmune cell types, such as bone marrow stroma, antigen-presenting cells including monocytes/macrophages and dendritic cells, epithelial cells, and fibroblasts.7 This wide expression of IL-15 in vivo is consistent with its role as an NK cell survival factor. After viral and bacterial infection of peripheral blood mononuclear cells in vitro, expression of IL-15 is up-regulated and activates NK cell cytotoxicity and cytokine production.7,29,30 In vivo neutralization of IL-15 in SCID mice before administration of lipopolysaccharide significantly reduced production of interferon-gamma by NK cells and mortality associated with the Shwartzman reaction, a fatal cytokine-induced shock.31 In the current study, we showed that in addition to activation of NK cell cytotoxicity and cytokine production, IL-15 is critical for survival of mature NK cells in vivo. Thus, up-regulation of IL-15 early during infection likely also alters NK cell homeostasis to favor an efficient innate immune response before the organism can mount an adaptive, T-cell-mediated response. Evidence has shown that IL-15 is also important for the survival and expansion of memory CD8+ T cells, in distinct contrast to IL-2, which promotes activation-induced cell death of these lymphocytes.32 The regulation of innate and adaptive immune lymphocyte homeostasis by the same cytokine indicates that IL-15 is essential for an efficient immune response and suggests a possible coordination of these two cell-mediated arms of the immune system.

In the current study, we used IL-15-/- mice to demonstrate that adoptively transferred wt NK cells do not survive in an IL-15-deficient environment. This effect likely depends primarily on the absence of IL-15 rather than other deficiencies, because treatment of IL-15-/- mice with exogenous IL-15 for one week can expand or differentiate and maintain the survival of endogenous NK cells in such mice.15 It is also possible, although unlikely, that transferred NK cells in IL-15-/- mice might traffic to areas other than the major NK cell compartments examined here, and this possibility cannot be excluded. Adoptive transfer experiments also revealed that wt NK cells did not undergo substantial proliferation in vivo 5 days after adoptive transfer. This is probably because the NK cells transferred in this study were mature resting lymphocytes that were not exposed to an activation signal. It would be interesting to use this system to evaluate NK cell proliferation in vivo after activation with stimuli such as administration of exogenous cytokines or during infection.

We found that signaling through the IL-2/15Rbeta chain is clearly important for regulation of NK cell survival by IL-15, because blocking this receptor in vivo resulted in a loss of NK cells of about 90%. The complete IL-15R heterotrimeric complex consists of a private high-affinity subunit, IL-15Ralpha , and the IL-2/15Rbeta and gamma c, which signal through Jak/STAT pathways as well as additional intracellular pathways similar to IL-2.7,33 Because IL-15Ralpha -/-, IL-2/15Rbeta -/-, and gamma c-/- mice all have severe NK cell deficiencies as the result of a failure to produce NK cells,16-18 it is difficult to assess the relative contributions of these receptor subunits to IL-15-induced NK cell survival. An in vivo study by Li et al34 examined the effects of IL-15R subunits on T-cell survival and showed that down-regulation of the gamma c is correlated with decreased expression of Bcl-2 and increased apoptosis. Other studies demonstrated activation of Bcl-2 by means of the IL-2/15Rbeta chain.35,36 Therefore, the maintenance of Bcl-2 that we observed in vitro could have been the result of signaling of IL-15 by means of the gamma c in concert with the IL-2/15Rbeta and might have contributed to the effects of IL-15 on NK cell survival. Previous evidence suggested that IL-15Ralpha is also capable of transducing an intracellular signal, and IL-15 binding of this receptor was shown to promote the survival of several cell lines, possibly by sequestering the TRAF2 death-cascade adapter or by activating nuclear factor-kappa B.12-14 Thus, the failure of NK cells to develop in IL-15Ralpha -/- mice may be due to the fact that the IL-15Rbeta gamma heterodimer lacks sufficient affinity for the usually low concentration of endogenous IL-15 to bind and signal, or because signaling through the isolated IL-15Ralpha chain is absent. Our data showing the disappearance of about 90% of mature NK cells with blockade of IL-15Rbeta signaling support the idea that the role of IL-15Ralpha in mature NK cell survival in vivo could be to confer high-affinity binding between the heterotrimeric complex and its ligand.

It is likely that IL-15 regulates NK cell differentiation and NK cell survival through distinct pathways. IL-15 is required for NK cell differentiation, but Bcl-2 does not appear to be required, because lymphocytes seem to develop normally in Bcl-2-/- mice,37 and global overexpression of Bcl-2 in IRF-1-/- mice (which lack inducible IL-15) or gamma c-/- mice does not restore NK cell development.38,39 However, Bcl-2 probably does function as a survival factor, because Bcl-2-/- mice rapidly lose their lymphocytes several weeks after birth37 and mature NK cells from mice globally overexpressing Bcl-2 were resistant to apoptosis induced by growth-factor starvation.26 In this study, we showed that IL-15 maintains murine NK cell levels of Bcl-2, and in a previous study, we found that IL-15-induced survival of human NK cells was lost when Bcl-2 was blocked in vitro.25 These results, along with our finding that Bcl-2tg NK cells are maintained in IL-15-/- mice, suggest that IL-15 activation of Bcl-2 is important for mature NK cell survival.

Our findings in this study provide the first in vivo evidence that IL-15 is necessary for NK cell survival and highlight the critical importance of this cytokine in overall NK cell homeostasis. On the basis of these results and what is already known about the role of IL-15 in NK cell development, we hypothesize that IL-15 may be a master regulator of NK cells, directing NK cell differentiation, homeostasis, and survival in vivo.


    Acknowledgments

We thank Kellie Archer for statistical analysis and Ivan K. Lukic, Charlene Mao, and Xiaotie Bu for excellent technical assistance.


    Footnotes

Submitted December 21, 2001; accepted June 19, 2002.

Prepublished online as Blood First Edition Paper, July 5, 2002; DOI 10.1182/blood-2001-12-0293.

Supported by grants CA-68458, CA-95426, and P30CA-16058 (M. A. Caligiuri) and RO1 AI46708 (H.L.A.) from the National Institutes of Health. M. A. Cooper, T.A.F., and J.B.V. are recipients of Medical Scientist Program Fellowships from The Ohio State University College of Medicine and Public Health.

The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 U.S.C. section 1734.

Reprints: Michael A. Caligiuri, The Ohio State University, 458A Starling-Loving Hall, 320 West 10th Ave, Columbus, OH 43210; e-mail: caligiuri-1{at}medctr.osu.edu.


    References
Top
Abstract
Introduction
Materials and methods
Results
Discussion
References

1. Smith HR, Idris AH, Yokoyama WM. Murine natural killer cell activation receptors. Immunol Rev. 2001;181:115-125[CrossRef][Medline] [Order article via Infotrieve].

2. Cooper MA, Fehniger TA, Caligiuri MA. The biology of human natural killer cell subsets. Trends Immunol. 2001;22:633-640[CrossRef][Medline] [Order article via Infotrieve].

3. Biron CA, Nguyen KB, Pien GC, Cousens LP, Salazar-Mather TP. Natural killer cells in antiviral defense: function and regulation by innate cytokines. Annu Rev Immunol. 1999;17:189-220[CrossRef][Medline] [Order article via Infotrieve].

4. Bancroft GJ. The role of natural killer cells in innate resistance to infection. Curr Opin Immunol. 1993;5:503-510[CrossRef][Medline] [Order article via Infotrieve].

5. Scharton-Kersten TM, Sher A. Role of natural killer cells in innate resistance to protozoan infections. Curr Opin Immunol. 1997;9:44-51[CrossRef][Medline] [Order article via Infotrieve].

6. Williams NS, Klem J, Puzanov IJ, et al. Natural killer cell differentiation: insights from knockout and transgenic mouse models and in vitro systems. Immunol Rev. 1998;165:47-61[CrossRef][Medline] [Order article via Infotrieve].

7. Fehniger TA, Caligiuri MA. Interleukin 15: biology and relevance to human disease. Blood. 2001;97:14-32[Free Full Text].

8. Burton JD, Bamford RN, Peters C, et al. A lymphokine, provisionally designated interleukin T and produced by a human adult T-cell leukemia line, stimulates T-cell proliferation and the induction of lymphokine-activated killer cells. Proc Natl Acad Sci U S A. 1994;91:4935-4939[Abstract/Free Full Text].

9. Grabstein KH, Eisenman J, Shanebeck K, et al. Cloning of a T cell growth factor that interacts with the beta chain of the interleukin-2 receptor. Science. 1994;264:965-968[Abstract/Free Full Text].

10. Di Santo JP, Kuhn R, Muller W. Common cytokine receptor gamma  chain (gamma c)-dependent cytokines: understanding in vivo functions by gene targeting. Immunol Rev. 1995;148:19-34[CrossRef][Medline] [Order article via Infotrieve].

11. Asao H, Okuyama C, Kumaki S, et al. Cutting edge: the common gamma -chain is an indispensable subunit of the IL-21 receptor complex. J Immunol. 2001;167:1-5[Abstract/Free Full Text].

12. Bulfone-Paus SS, Bulanova E, Pohl T, et al. Death deflected: IL-15 inhibits TNF-alpha -mediated apoptosis in fibroblasts by TRAF2 recruitment to the IL-15Ralpha chain. FASEB J. 1999;13:1575-1585[Abstract/Free Full Text].

13. Pereno R, Gaggero A, Scudeletti M, et al. IL-15/IL-15R alpha  intracellular trafficking in human cells and protection from apoptosis. Ann N Y Acad Sci. 1999;876:236-245[CrossRef][Medline] [Order article via Infotrieve].

14. Pereno R, Giron-Michel J, Gaggero A, et al. IL-15/IL-15Ralpha intracellular trafficking in human melanoma cells and signal transduction through the IL-15Ralpha . Oncogene. 2000;19:5153-5162[CrossRef][Medline] [Order article via Infotrieve].

15. Kennedy MK, Glaccum M, Brown SN, et al. Reversible defects in natural killer and memory CD8 T cell lineages in interleukin 15-deficient mice. J Exp Med. 2000;191:771-780[Abstract/Free Full Text].

16. Lodolce JP, Boone DL, Chai S, et al. IL-15 receptor maintains lymphoid homeostasis by supporting lymphocyte homing and proliferation. Immunity. 1998;9:669-676[CrossRef][Medline] [Order article via Infotrieve].

17. Suzuki H, Duncan GS, Takimoto H, Mak TW. Abnormal development of intestinal intraepithelial lymphocytes and peripheral natural killer cells in mice lacking the IL-2 receptor beta  chain. J Exp Med. 1997;185:499-505[Abstract/Free Full Text].

18. DiSanto JP, Muller W, Guy-Grand D, Fischer A, Rajewsky K. Lymphoid development in mice with a targeted deletion of the interleukin 2 receptor gamma  chain. Proc Natl Acad Sci U S A. 1995;92:377-381[Abstract/Free Full Text].

19. Park SY, Saijo K, Takahashi T, et al. Developmental defects of lymphoid cells in Jak3 kinase-deficient mice. Immunity. 1995;3:771-782[CrossRef][Medline] [Order article via Infotrieve].

20. Nosaka T, van Deursen JM, Tripp RA, et al. Defective lymphoid development in mice lacking Jak3. Science. 1995;270:800-802[Abstract/Free Full Text].

21. Fehniger TA, Suzuki K, Ponnappan A, et al. Fatal leukemia in interleukin 15 transgenic mice follows early expansions in natural killer and memory phenotype CD8+ T cells. J Exp Med. 2001;193:219-231[Abstract/Free Full Text].

22. Marks-Konczalik J, Dubois S, Losi JM, et al. IL-2-induced activation-induced cell death is inhibited in IL-15 transgenic mice. Proc Natl Acad Sci U S A. 2000;97:11445-11450[Abstract/Free Full Text].

23. Gilmour KC, Fujii H, Cranston T, Davies EG, Kinnon C, Gaspar HB. Defective expression of the interleukin-2/interleukin-15 receptor beta  subunit leads to a natural killer cell-deficient form of severe combined immunodeficiency. Blood. 2001;98:877-879[Abstract/Free Full Text].

24. Kundig TM, Schorle H, Bachmann MF, Hengartner H, Zinkernagel RM, Horak I. Immune responses in interleukin-2-deficient mice. Science. 1993;262:1059-1061[Abstract/Free Full Text].

25. Carson WE, Fehniger TA, Haldar S, et al. A potential role for interleukin-15 in the regulation of human natural killer cell survival. J Clin Invest. 1997;99:937-943[Medline] [Order article via Infotrieve].

26. Domen J, Gandy KL, Weissman IL. Systemic overexpression of BCL-2 in the hematopoietic system protects transgenic mice from the consequences of lethal irradiation. Blood. 1998;91:2272-2282[Abstract/Free Full Text].

27. Tanaka T, Tsudo M, Karasuyama H, et al. A novel monoclonal antibody against murine IL-2 receptor beta -chain. Characterization of receptor expression in normal lymphoid cells and EL-4 cells. J Immunol. 1991;147:2222-2228[Abstract].

28. Kasaian MT, Whitters MJ, Carter LL, et al. IL-21 limits NK cell responses and promotes antigen-specific T cell activation: a mediator of the transition from innate to adaptive immunity. Immunity. 2002;16:559-569[CrossRef][Medline] [Order article via Infotrieve].

29. Fawaz LM, Sharif-Askari E, Menezes J. Up-regulation of NK cytotoxic activity via IL-15 induction by different viruses: a comparative study. J Immunol. 1999;163:4473-4480[Abstract/Free Full Text].

30. Carson WE, Ross ME, Baiocchi RA, et al. Endogenous production of interleukin 15 by activated human monocytes is critical for optimal production of interferon-gamma by natural killer cells in vitro. J Clin Invest. 1995;96:2578-2582[Medline] [Order article via Infotrieve].

31. Fehniger TA, Yu H, Cooper MA, Suzuki K, Shah MH, Caligiuri MA. Cutting edge: IL-15 costimulates the generalized Shwartzman reaction and innate immune IFN-gamma production in vivo. J Immunol. 2000;164:1643-1647[Abstract/Free Full Text].

32. Waldmann TA, Dubois S, Tagaya Y. Contrasting roles of IL-2 and IL-15 in the life and death of lymphocytes: implications for immunotherapy. Immunity. 2001;14:105-110[Medline] [Order article via Infotrieve].

33. Giri JG, Ahdieh M, Eisenman J, et al. Utilization of the beta  and gamma  chains of the IL-2 receptor by the novel cytokine IL-15. EMBO J. 1994;13:2822-2830[Medline] [Order article via Infotrieve].

34. Li XC, Demirci G, Ferrari-Lacraz S, et al. IL-15 and IL-2: a matter of life and death for T cells in vivo. Nat Med. 2001;7:114-118[CrossRef][Medline] [Order article via Infotrieve].

35. Van Parijs L, Refaeli Y, Lord JD, Nelson BH, Abbas AK, Baltimore D. Uncoupling IL-2 signals that regulate T cell proliferation, survival, and Fas-mediated activation-induced cell death. Immunity. 1999;11:281-288[CrossRef][Medline] [Order article via Infotrieve].

36. Lord JD, McIntosh BC, Greenberg PD, Nelson BH. The IL-2 receptor promotes lymphocyte proliferation and induction of the c-myc, bcl-2, and bcl-x genes through the trans-activation domain of Stat5. J Immunol. 2000;164:2533-2541[Abstract/Free Full Text].

37. Veis DJ, Sorenson CM, Shutter JR, Korsmeyer SJ. Bcl-2-deficient mice demonstrate fulminant lymphoid apoptosis, polycystic kidneys, and hypopigmented hair. Cell. 1993;75:229-240[CrossRef][Medline] [Order article via Infotrieve].

38. Ohteki T, Maki C, Koyasu S. Overexpression of Bcl-2 differentially restores development of thymus-derived CD4-8+ T cells and intestinal intraepithelial T cells in IFN-regulatory factor-1-deficient mice. J Immunol. 2001;166:6509-6513[Abstract/Free Full Text].

39. Kondo M, Akashi K, Domen J, Sugamura K, Weissman IL. Bcl-2 rescues T lymphopoiesis, but not B or NK cell development, in common gamma  chain-deficient mice. Immunity. 1997;7:155-162[CrossRef][Medline] [Order article via Infotrieve].

© 2002 by The American Society of Hematology.
 

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
J. Immunol.Home page
E. F. Castillo, S. W. Stonier, L. Frasca, and K. S. Schluns
Dendritic Cells Support the In Vivo Development and Maintenance of NK Cells via IL-15 Trans-Presentation
J. Immunol., October 15, 2009; 183(8): 4948 - 4956.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
J. C. Sun, A. Ma, and L. L. Lanier
Cutting Edge: IL-15-Independent NK Cell Response to Mouse Cytomegalovirus Infection
J. Immunol., September 1, 2009; 183(5): 2911 - 2914.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
D. L. Hodge, J. Yang, M. D. Buschman, P. M. Schaughency, H. Dang, W. Bere, Y. Yang, R. Savan, J. J. Subleski, X.-M. Yin, et al.
Interleukin-15 Enhances Proteasomal Degradation of Bid in Normal Lymphocytes: Implications for Large Granular Lymphocyte Leukemias
Cancer Res., May 1, 2009; 69(9): 3986 - 3994.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
F. Cichocki, R. J. Hanson, T. Lenvik, M. Pitt, V. McCullar, H. Li, S. K. Anderson, and J. S. Miller
The transcription factor c-Myc enhances KIR gene transcription through direct binding to an upstream distal promoter element
Blood, April 2, 2009; 113(14): 3245 - 3253.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
J. I. Aguilo, J. Garaude, J. Pardo, M. Villalba, and A. Anel
Protein Kinase C-{theta} Is Required for NK Cell Activation and In Vivo Control of Tumor Progression
J. Immunol., February 15, 2009; 182(4): 1972 - 1981.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
M. A. Cooper, J. M. Elliott, P. A. Keyel, L. Yang, J. A. Carrero, and W. M. Yokoyama
Cytokine-induced memory-like natural killer cells
PNAS, February 10, 2009; 106(6): 1915 - 1919.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
M. Cheng, H. N. Charoudeh, P. Brodin, Y. Tang, T. Lakshmikanth, P. Hoglund, S. E. W. Jacobsen, and E. Sitnicka
Distinct and Overlapping Patterns of Cytokine Regulation of Thymic and Bone Marrow-Derived NK Cell Development
J. Immunol., February 1, 2009; 182(3): 1460 - 1468.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
J. Rowley, A. Monie, C.-F. Hung, and T.-C. Wu
Inhibition of Tumor Growth by NK1.1+ Cells and CD8+ T Cells Activated by IL-15 through Receptor {beta}/Common {gamma} Signaling in trans
J. Immunol., December 15, 2008; 181(12): 8237 - 8247.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
M. Yawata, N. Yawata, M. Draghi, F. Partheniou, A.-M. Little, and P. Parham
MHC class I-specific inhibitory receptors and their ligands structure diverse human NK-cell repertoires toward a balance of missing self-response
Blood, September 15, 2008; 112(6): 2369 - 2380.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
H. J. Pegram, J. T. Jackson, M. J. Smyth, M. H. Kershaw, and P. K. Darcy
Adoptive Transfer of Gene-Modified Primary NK Cells Can Specifically Inhibit Tumor Progression In Vivo
J. Immunol., September 1, 2008; 181(5): 3449 - 3455.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
J. B. Sunwoo, S. Kim, L. Yang, T. Naik, D. A. Higuchi, J. L. Rubenstein, and W. M. Yokoyama
Distal-less homeobox transcription factors regulate development and maturation of natural killer cells
PNAS, August 5, 2008; 105(31): 10877 - 10882.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
C.-L. Small, S. McCormick, N. Gill, K. Kugathasan, M. Santosuosso, N. Donaldson, D. E. Heinrichs, A. Ashkar, and Z. Xing
NK Cells Play a Critical Protective Role in Host Defense against Acute Extracellular Staphylococcus aureus Bacterial Infection in the Lung
J. Immunol., April 15, 2008; 180(8): 5558 - 5568.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
M. Terme, N. Chaput, B. Combadiere, A. Ma, T. Ohteki, and L. Zitvogel
Regulatory T Cells Control Dendritic Cell/NK Cell Cross-Talk in Lymph Nodes at the Steady State by Inhibiting CD4+ Self-Reactive T Cells
J. Immunol., April 1, 2008; 180(7): 4679 - 4686.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
M. T. M. Vossen, M. Matmati, K. M. L. Hertoghs, P. A. Baars, M.-R. Gent, G. Leclercq, J. Hamann, T. W. Kuijpers, and R. A. W. van Lier
CD27 Defines Phenotypically and Functionally Different Human NK Cell Subsets
J. Immunol., March 15, 2008; 180(6): 3739 - 3745.
[Abstract] [Full Text] [PDF]


Home page
JEMHome page
C. A.J. Vosshenrich, S. Lesjean-Pottier, M. Hasan, O. Richard-Le Goff, E. Corcuff, O. Mandelboim, and J. P. Di Santo
CD11cloB220+ interferon-producing killer dendritic cells are activated natural killer cells
J. Exp. Med., October 29, 2007; 204(11): 2569 - 2578.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
A. L. Zhang, P. Colmenero, U. Purath, C. Teixeira de Matos, W. Hueber, L. Klareskog, I. H. Tarner, E. G. Engleman, and K. Soderstrom
Natural killer cells trigger differentiation of monocytes into dendritic cells
Blood, October 1, 2007; 110(7): 2484 - 2493.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
M. Prlic, D. Kamimura, and M. J. Bevan
Rapid generation of a functional NK-cell compartment
Blood, September 15, 2007; 110(6): 2024 - 2026.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
T. Wang, J. W. Holland, A. Carrington, J. Zou, and C. J. Secombes
Molecular and Functional Characterization of IL-15 in Rainbow Trout Oncorhynchus mykiss: A Potent Inducer of IFN-{gamma} Expression in Spleen Leukocytes
J. Immunol., August 1, 2007; 179(3): 1475 - 1488.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
L. Chiossone, C. Vitale, F. Cottalasso, S. Moretti, B. Azzarone, L. Moretta, and M. C. Mingari
Molecular analysis of the methylprednisolone-mediated inhibition of NK-cell function: evidence for different susceptibility of IL-2- versus IL-15-activated NK cells
Blood, May 1, 2007; 109(9): 3767 - 3775.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
K. Nakazato, H. Yamada, T. Yajima, Y. Kagimoto, H. Kuwano, and Y. Yoshikai
Enforced Expression of Bcl-2 Partially Restores Cell Numbers but Not Functions of TCR{gamma}{delta} Intestinal Intraepithelial T Lymphocytes in IL-15-Deficient Mice
J. Immunol., January 15, 2007; 178(2): 757 - 764.
[Abstract] [Full Text] [PDF]


Home page
PediatricsHome page
A. Bernasconi, R. Marino, A. Ribas, J. Rossi, M. Ciaccio, M. Oleastro, A. Ornani, R. Paz, M. A. Rivarola, M. Zelazko, et al.
Characterization of Immunodeficiency in a Patient With Growth Hormone Insensitivity Secondary to a Novel STAT5b Gene Mutation
Pediatrics, November 1, 2006; 118(5): e1584 - e1592.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
J. O. Richards, X. Chang, B. W. Blaser, M. A. Caligiuri, P. Zheng, and Y. Liu
Tumor growth impedes natural-killer-cell maturation in the bone marrow
Blood, July 1, 2006; 108(1): 246 - 252.
[Abstract] [Full Text] [PDF]


Home page
JEMHome page
M. Bajenoff, B. Breart, A. Y.C. Huang, H. Qi, J. Cazareth, V. M. Braud, R. N. Germain, and N. Glaichenhaus
Natural killer cell behavior in lymph nodes revealed by static and real-time imaging
J. Exp. Med., March 20, 2006; 203(3): 619 - 631.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
T. Yajima, K. Yoshihara, K. Nakazato, S. Kumabe, S. Koyasu, S. Sad, H. Shen, H. Kuwano, and Y. Yoshikai
IL-15 Regulates CD8+ T Cell Contraction during Primary Infection
J. Immunol., January 1, 2006; 176(1): 507 - 515.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
S. Cooley, V. McCullar, R. Wangen, T. L. Bergemann, S. Spellman, D. J. Weisdorf, and J. S. Miller
KIR reconstitution is altered by T cells in the graft and correlates with clinical outcomes after unrelated donor transplantation
Blood, December 15, 2005; 106(13): 4370 - 4376.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
J. D. French, C. L. Roark, W. K. Born, and R. L. O'Brien
{gamma}{delta} T cell homeostasis is established in competition with {alpha}{beta} T cells and NK cells
PNAS, October 11, 2005; 102(41): 14741 - 14746.
[Abstract] [Full Text] [PDF]


Home page
J. Virol.Home page
U.-C. Meier, R. E. Owen, E. Taylor, A. Worth, N. Naoumov, C. Willberg, K. Tang, P. Newton, P. Pellegrino, I. Williams, et al.
Shared Alterations in NK Cell Frequency, Phenotype, and Function in Chronic Human Immunodeficiency Virus and Hepatitis C Virus Infections
J. Virol., October 1, 2005; 79(19): 12365 - 12374.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
C. Imai, S. Iwamoto, and D. Campana
Genetic modification of primary natural killer cells overcomes inhibitory signals and induces specific killing of leukemic cells
Blood, July 1, 2005; 106(1): 376 - 383.
[Abstract] [Full Text] [PDF]


Home page
Infect. Immun.Home page
R. Ing, P. Gros, and M. M. Stevenson
Interleukin-15 Enhances Innate and Adaptive Immune Responses to Blood-Stage Malaria Infection in Mice
Infect. Immun., May 1, 2005; 73(5): 3172 - 3177.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
A. Velardi
NK cell adoptive immunotherapy
Blood, April 15, 2005; 105(8): 3006 - 3006.
[Full Text] [PDF]


Home page
BloodHome page
J. S. Miller, Y. Soignier, A. Panoskaltsis-Mortari, S. A. McNearney, G. H. Yun, S. K. Fautsch, D. McKenna, C. Le, T. E. Defor, L. J. Burns, et al.
Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer
Blood, April 15, 2005; 105(8): 3051 - 3057.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
B. W. Blaser, S. Roychowdhury, D. J. Kim, N. R. Schwind, D. Bhatt, W. Yuan, D. F. Kusewitt, A. K. Ferketich, M. A. Caligiuri, and M. Guimond
Donor-derived IL-15 is critical for acute allogeneic graft-versus-host disease
Blood, January 15, 2005; 105(2): 894 - 901.
[Abstract] [Full Text] [PDF]


Home page
J. Leukoc. Biol.Home page
M. Conklyn, C. Andresen, P. Changelian, and E. Kudlacz
The JAK3 inhibitor CP-690550 selectively reduces NK and CD8+ cell numbers in cynomolgus monkey blood following chronic oral dosing
J. Leukoc. Biol., December 1, 2004; 76(6): 1248 - 1255.
[Abstract] [Full Text] [PDF]


Home page
Ann Rheum DisHome page
J J O'Shea
Targeting the Jak/STAT pathway for immunosuppression
Ann Rheum Dis, November 1, 2004; 63(suppl_2): ii67 - ii71.
[Full Text] [PDF]


Home page
JEMHome page
P. R. Burkett, R. Koka, M. Chien, S. Chai, D. L. Boone, and A. Ma
Coordinate Expression and Trans Presentation of Interleukin (IL)-15R{alpha} and IL-15 Supports Natural Killer Cell and Memory CD8+ T Cell Homeostasis
J. Exp. Med., October 4, 2004; 200(7): 825 - 834.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
R. Koka, P. Burkett, M. Chien, S. Chai, D. L. Boone, and A. Ma
Cutting Edge: Murine Dendritic Cells Require IL-15R{alpha} to Prime NK Cells
J. Immunol., September 15, 2004; 173(6): 3594 - 3598.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
S. H. Robbins, M. S. Tessmer, T. Mikayama, and L. Brossay
Expansion and Contraction of the NK Cell Compartment in Response to Murine Cytomegalovirus Infection
J. Immunol., July 1, 2004; 173(1): 259 - 266.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
K. S. Schluns, E. C. Nowak, A. Cabrera-Hernandez, L. Puddington, L. Lefrancois, and H. L. Aguila
Distinct cell types control lymphoid subset development by means of IL-15 and IL-15 receptor {alpha} expression
PNAS, April 13, 2004; 101(15): 5616 - 5621.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
J. Brady, Y. Hayakawa, M. J. Smyth, and S. L. Nutt
IL-21 Induces the Functional Maturation of Murine NK Cells
J. Immunol., February 15, 2004; 172(4): 2048 - 2058.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
A. M. Jamieson, P. Isnard, J. R. Dorfman, M. C. Coles, and D. H. Raulet
Turnover and Proliferation of NK Cells in Steady State and Lymphopenic Conditions
J. Immunol., January 15, 2004; 172(2): 864 - 870.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
T. Kawamura, R. Koka, A. Ma, and V. Kumar
Differential Roles for IL-15R {alpha}-Chain in NK Cell Development and Ly-49 Induction
J. Immunol., November 15, 2003; 171(10): 5085 - 5090.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
J. Barlic, J. M. Sechler, and P. M. Murphy
IL-15 and IL-2 oppositely regulate expression of the chemokine receptor CX3CR1
Blood, November 15, 2003; 102(10): 3494 - 3503.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
H. Hiramatsu, R. Nishikomori, T. Heike, M. Ito, K. Kobayashi, K. Katamura, and T. Nakahata
Complete reconstitution of human lymphocytes from cord blood CD34+ cells using the NOD/SCID/{gamma}cnull mice model
Blood, August 1, 2003; 102(3): 873 - 880.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
T. Ranson, C. A. J. Vosshenrich, E. Corcuff, O. Richard, W. Muller, and J. P. Di Santo
IL-15 is an essential mediator of peripheral NK-cell homeostasis
Blood, June 15, 2003; 101(12): 4887 - 4893.
[Abstract] [Full Text] [PDF]


Home page
JEMHome page
M. Prlic, B. R. Blazar, M. A. Farrar, and S. C. Jameson
In Vivo Survival and Homeostatic Proliferation of Natural Killer Cells
J. Exp. Med., April 21, 2003; 197(8): 967 - 976.
[Abstract] [Full Text] [PDF]


Home page
JEMHome page
R. Koka, P. R. Burkett, M. Chien, S. Chai, F. Chan, J. P. Lodolce, D. L. Boone, and A. Ma
Interleukin (IL)-15R{alpha}-deficient Natural Killer Cells Survive in Normal but Not IL-15R{alpha}-deficient Mice
J. Exp. Med., April 21, 2003; 197(8): 977 - 984.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
T. Ranson, C. A. J. Vosshenrich, E. Corcuff, O. Richard, V. Laloux, A. Lehuen, and J. P. Di Santo
IL-15 availability conditions homeostasis of peripheral natural killer T cells
PNAS, March 4, 2003; 100(5): 2663 - 2668.
[Abstract] [Full Text] [PDF]


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
2001-12-0293v1
100/10/3633    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Right arrow Rights and Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Cooper, M. A.
Right arrow Articles by Caligiuri, M. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Cooper, M. A.
Right arrow Articles by Caligiuri, M. A.
Related Collections
Right arrow Immunobiology
Right arrow Apoptosis
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

 click for free articles
home about blood authors subscriptions permissions advertising public access contact us
  Copyright © 2002 by American Society of Hematology         Online ISSN: 1528-0020